Yahoo
    NasdaqCM - BOATS Real Time Price USD

    Nuvectis Pharma, Inc. (NVCT)

    18.48 -0.09 (-0.48%)
    At close: October 30 at 4:00:01 PM EDT
    19.58 +1.10 (+5.95%)
    Overnight: 9:30:40 PM EST
    Trade NVCT on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for NVCT
    Chart does not reflect overnight price.
    • Previous Close 18.57
    • Open 18.46
    • Bid 13.47 x 200
    • Ask 23.56 x 200
    • Day's Range 18.20 - 18.92
    • 52 Week Range 5.55 - 29.27
    • Volume 168,908
    • Avg. Volume 199,534
    • Market Cap (intraday) 603.262M
    • Beta (5Y Monthly) -0.24
    • PE Ratio (TTM) --
    • EPS (TTM) -1.31
    • Earnings Date (est.) Nov 3, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 35.40
    • Zacks Rating Neutral

    Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

    www.nuvectis.com

    16

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about Nuvectis Pharma, Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    NVCT
    144.77%
    S&P 500 (^GSPC)
    10.73%

    1-Year Return

    NVCT
    178.31%
    S&P 500 (^GSPC)
    11.11%

    3-Year Return

    NVCT
    120.79%
    S&P 500 (^GSPC)
    81.91%

    5-Year Return

    NVCT
    367.85%
    S&P 500 (^GSPC)
    64.59%

    Earnings Trends

    View More

    Earnings Per Share (GAAP)

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q1 FY26
    Revenue --
    Earnings -6.05M
    Profit Margin 0.00%

    Q2

    FY25

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    -6M
    -4M
    -2M
    0
    0.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    30.00
    35.40 Average
    18.48 Current
    40.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 9/24/2026
    Analyst HC Wainwright & Co.
    Rating Action Reiterates
    Rating Buy
    Price Action Maintains
    Price Target 39 -> 39
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      0.00%

    • Return on Assets (ttm)

      -73.07%

    • Return on Equity (ttm)

      -214.58%

    • Revenue (ttm)

      --

    • Net Income Avi to Common (ttm)

      -30.27M

    • Diluted EPS (ttm)

      -1.31

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      22.16M

    • Total Debt/Equity (mrq)

      --

    • Levered Free Cash Flow (ttm)

      -8.89M

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    IMMX
    NRSN
    ANGH
    TRDA
    FHTX
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: